TCL1A Rekombinanter Antikörper
TCL1A Rekombinant Antikörper für WB, IHC, IF/ICC, FC (Intra), Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human
Anwendung
WB, IHC, IF/ICC, FC (Intra), Indirect ELISA
Konjugation
Unkonjugiert
CloneNo.
242623A9
Kat-Nr. : 85129-5-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
85129-5-PBS bindet in WB, IHC, IF/ICC, FC (Intra), Indirect ELISA TCL1A und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Rekombinant |
| Typ | Antikörper |
| Immunogen | TCL1A fusion protein Ag0786 |
| Vollständiger Name | T-cell leukemia/lymphoma 1A |
| Berechnetes Molekulargewicht | 13 kDa |
| Beobachtetes Molekulargewicht | 15 kDa |
| GenBank-Zugangsnummer | BC005831 |
| Gene symbol | TCL1A |
| Gene ID (NCBI) | 8115 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-A-Reinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
TCL1A, also named as TCL1 and p14 TCL1, enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell survival. TCL1A immunodetection is an independent marker of adverse outcome that could be used in routine settings for the management of DLCL patients. TCL1A expression is correlated with shorter time to treatment in chronic lymphocytic leukemia cases and shorter lymphoma-specific survival in mantle cell lymphoma series. It is a potential therapeutic target.









